供者骨髓来源巨噬细胞在同种异体移植患者中枢神经系统中的植入
研究开发了免疫组化与XY荧光原位杂交联合检测法,在19例接受同种异体干细胞移植的女性患者大脑皮质中检测供者细胞,发现男性供者细胞占总细胞0.14%–3.0%或小胶质细胞的1.2%–25%,至少80%表达小胶质细胞标志物IBA-1,且植入比例与预处理方案及移植次数和生存期相关。
要点
- 联合免疫组化与XY荧光原位杂交可检测并定量脑内供者骨髓来源巨噬细胞。
- 供者细胞占小胶质细胞1.2%–25%,至少80%表达IBA-1。
- 放疗为基础清髓预处理者供者细胞平均占小胶质细胞8.1%,非清髓者仅1.3%。
核心结论
- 同种异体移植后供者骨髓来源巨噬细胞可植入患者大脑皮质并表达小胶质细胞标志物,植入效率提示未来可研究小胶质细胞替代作为中枢神经系统疾病的治疗选择。
研究设计与样本
- 采用新型联合免疫组化与XY荧光原位杂交法,检测19例接受同种异体干细胞移植的女性患者大脑皮质中的供者细胞。
主要发现
- 男性供者细胞占总细胞0.14%–3.0%,占小胶质细胞1.2%–25%。
- 至少80%的供者细胞表达小胶质细胞标志物离子钙结合衔接分子-1(IBA-1)。
- 放疗为基础清髓预处理者供者细胞平均占小胶质细胞8.1%,非清髓预处理者平均仅1.3%。
- 白消安或曲奥舒凡为基础清髓预处理者供者细胞平均占小胶质细胞6.8%,与全身照射为基础预处理者相似。
- 接受多次移植及移植后生存期最长的患者供者植入水平最高,供者细胞平均占小胶质细胞16.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematopoietic stem cell transplantation is a well-known treatment for hematologic malignancies, wherein nascent stem cells provide regenerating marrow and immunotherapy against the tumor. The progeny of hematopoietic stem cells also populate a wide spectrum of tissues, including the brain, as bone marrow-derived macrophages similar to microglial cells. We developed a sensitive and novel combined immunohistochemistry (IHC) and XY fluorescence in situ hybridization assay to detect, quantify, and characterize donor cells in the cerebral cortices of 19 female patients who underwent allogeneic stem cell transplantation. We showed that the number of male donor cells ranged from 0.14% to 3.0% of the total cells or from 1.2% to 25% of microglial cells. Using tyramide-based fluorescent IHC, we found that at least 80% of the donor cells expressed the microglial marker ionized calcium-binding adapter molecule-1, consistent with bone marrow-derived macrophages. The percentage of donor cells was related to pretransplantation conditioning; donor cells from radiation-based myeloablative cases averaged 8.1% of microglial cells, whereas those from nonmyeloablative cases averaged only 1.3%. The number of donor cells in patients conditioned with busulfan- or treosulfan-based myeloablation was similar to that in total body irradiation-based conditioning; donor cells averaged 6.8% of the microglial cells. Notably, patients who received multiple transplantations and those with the longest posttransplantation survival had the highest level of donor engraftment, with donor cells averaging 16.3% of the microglial cells. Our work represents the largest study characterizing bone marrow-derived macrophages in patients after transplantation. The efficiency of engraftment observed in our study warrants future research on microglial replacement as a therapeutic option for disorders of the central nervous system.
引用
- Loeb AM, Pattwell SS, Meshinchi S, et al. Donor bone marrow-derived macrophage engraftment into the central nervous system of patients following allogeneic transplantation. Blood Adv. 2023. PMID: 37315172. doi:10.1182/bloodadvances.2023010409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。